Sunesis Shifts Focus to Flagship PDK1 Inhibitor

https://biopharmajournal.com/2020/07/06/sunesis-pharmaceuticals-inc-nasdaqsnss-reveals-plan-to-discontinue-its-vecabrutinib-program/
JOIN OUR MAILING LIST